BACKGROUND: HIV-1-infected patients can be superinfected with additional HIV-1 variants. Therapy failure can be the consequence of an infection with a resistant strain. METHODS: A patient was diagnosed with a recent HIV-1 infection in April 2005 and subsequently clinically monitored. HIV-1 evolution was studied by population sequencing of the first 984 bases of the pol gene as well as 454 ultra-deep pyrosequencing (UDPS) of parts of the pol and env genes. RESULTS: The patient was diagnosed with a wild-type HIV-1 strain, but experienced rapid virological failure after initiating a non-nucleoside reverse transcriptase inhibitor (NNRTI)-based treatment regimen 3 years later. Population sequencing and UDPS revealed the presence of a second HIV-1 strain with a Y188L NNRTI resistance mutation in a sample obtained shortly prior to initiation of therapy. Phylogenetic analyses showed that the two HIV-1 strains were genetically distinct, providing evidence for superinfection. CONCLUSIONS: The virological treatment failure in this patient was probably due to the superinfection with an NNRTI-resistant HIV-1 variant. Superinfection with drug-resistant strains can undermine HIV-1 treatment regimens selected on the basis of resistance testing at diagnosis. Patients, especially in high-risk groups, as well as their clinicians, should be aware of the risks and dangers of superinfections.
BACKGROUND:HIV-1-infectedpatients can be superinfected with additional HIV-1 variants. Therapy failure can be the consequence of an infection with a resistant strain. METHODS: A patient was diagnosed with a recent HIV-1 infection in April 2005 and subsequently clinically monitored. HIV-1 evolution was studied by population sequencing of the first 984 bases of the pol gene as well as 454 ultra-deep pyrosequencing (UDPS) of parts of the pol and env genes. RESULTS: The patient was diagnosed with a wild-type HIV-1 strain, but experienced rapid virological failure after initiating a non-nucleoside reverse transcriptase inhibitor (NNRTI)-based treatment regimen 3 years later. Population sequencing and UDPS revealed the presence of a second HIV-1 strain with a Y188L NNRTI resistance mutation in a sample obtained shortly prior to initiation of therapy. Phylogenetic analyses showed that the two HIV-1 strains were genetically distinct, providing evidence for superinfection. CONCLUSIONS: The virological treatment failure in this patient was probably due to the superinfection with an NNRTI-resistant HIV-1 variant. Superinfection with drug-resistant strains can undermine HIV-1 treatment regimens selected on the basis of resistance testing at diagnosis. Patients, especially in high-risk groups, as well as their clinicians, should be aware of the risks and dangers of superinfections.
Authors: Fransje A Koning; Anjna Badhan; Simon Shaw; Martin Fisher; Jean L Mbisa; Patricia A Cane Journal: AIDS Res Hum Retroviruses Date: 2013-04-18 Impact factor: 2.205
Authors: Aubin J Nanfack; Andrew D Redd; Jude S Bimela; Genesis Ncham; Emmanuel Achem; Andrew N Banin; Allison R Kirkpatrick; Stephen F Porcella; Lucy A Agyingi; Josephine Meli; Vittorio Colizzi; Arthur Nádas; Miroslaw K Gorny; Phillipe N Nyambi; Thomas C Quinn; Ralf Duerr Journal: J Clin Microbiol Date: 2017-06-28 Impact factor: 5.948
Authors: Mariya V Sivay; Philip J Palumbo; Yinfeng Zhang; Vanessa Cummings; Xu Guo; Erica L Hamilton; Laura McKinstry; Arthur Ogendo; Noel Kayange; Ravindre Panchia; Karen Dominguez; Ying Q Chen; Theodorus G M Sandfort; Susan H Eshleman Journal: Clin Infect Dis Date: 2021-07-01 Impact factor: 9.079
Authors: Godefroid Mulakilwa Ali Musema; Pierre Zalagile Akilimali; Takaisi Kikuni Ntonbo Za Balega; Désiré Tshala-Katumbay; Paul-Samson Dikasa Lusamba Journal: Int J Environ Res Public Health Date: 2022-02-11 Impact factor: 3.390